GLPBio

(S)-(-)-Levamisole

Catalog No.: GC64735Purity:>97.00%
COASDSData Sheet
(S)-(-)-Lévamisole (Lévamisole), un agent anthelminthique aux propriétés immunomodulatrices.

Les produits sont exclusivement destinés à la recherche. Ils ne doivent pas être utilisés chez l’être humain. Nous ne vendons pas aux patients.

(S)-(-)-Levamisole
Cas No.: 14769-73-4
10mM (in 1mL DMSO)In Stock
$11.00
1
100mgIn Stock
$10.00
1
500mgIn Stock
$20.00
1
1gIn Stock
$31.00
1
5gIn Stock
$64.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

Aucune citation n’est actuellement disponible pour ce produit. Vous trouverez ci-dessous une sélection de publications citant des produits GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

(S)-(-)-Levamisole is an anthelmintic that selectively activates nematode acetylcholine ion channel receptors[1]. (S)-(-)-Levamisole works as a nicotinic acetylcholine receptor agonist, causing muscle spasms and paralysis in parasitic worms, enhances the function of macrophages, T lymphocytes, and T cell maturation as well as cytokine production (IL-1), and induces a shift towards Th1 cytokines[2]. (S)-(-)-Levamisole has been widely used in immunomodulation to prevent parasitic, viral and bacterial infections[3].

In vitro, (S)-(-)-Levamisole treatment (5mM) for 24 hours induced apoptosis in human umbilical vein endothelial cells (HUVEC), and decreased the mRNA expression of p53, clusterin, and ET-1[4]. Incubation with (S)-(-)-Levamisole (100µM) for 24 hours suppressed lipopolysaccharide (LPS)-stimulated PGE2 production and reduced LPS-induced COX-2 mRNA expression and COX-2 protein levels in Colon 205 cells[5].

In vivo, (S)-(-)-Levamisole treatment via subcutaneous injection at a dose of 12mg/kg dose, three times a week for 4 weeks, inhibited the growth of HABC-1 tumors in BALB/cA nu/nu mice[6]. Oral administration of (S)-(-)-Levamisole (20mg/kg) daily for 14 days alleviated the cytopenia in the mouse model of immune-mediated bone marrow failure and prolonged the survival period[7].

References:
[1] Martin R J, Robertson A P, Buxton S K, et al. Levamisole receptors: a second awakening[J]. Trends in parasitology, 2012, 28(7): 289-296.
[2] Brunt T M, van den Berg J, Pennings E, et al. Adverse effects of levamisole in cocaine users: a review and risk assessment[J]. Archives of Toxicology, 2017, 91(6): 2303-2313.
[3] Scheinfeld N, Rosenberg J D, Weinberg J M. Levamisole in dermatology: a review[J]. American Journal of Clinical Dermatology, 2004, 5(2): 97-104.
[4] Artwohl M, Hölzenbein T, Wagner L, et al. Levamisole induced apoptosis in cultured vascular endothelial cells[J]. British journal of pharmacology, 2000, 131(8): 1577-1583.
[5] Liu M S C Y, Lai M S Y Y, Lo M D C J. Levamisole modulates prostaglandin E2 production and cyclooxygenase II gene expression in human colonic cancer cells[J]. Journal of Surgical Research, 2004, 117(2): 223-231.
[6] Friis T, Engel A M, Klein B M, et al. Levamisole inhibits angiogenesis in vitro and tumor growth in vivo[J]. Angiogenesis, 2005, 8(1): 25-34.
[7] Wang J, Liu J, Wang M, et al. Levamisole suppresses CD4+ T-cell proliferation and antigen-presenting cell Activation in Aplastic Anemia by Regulating the JAK/STAT and TLR Signaling Pathways[J]. Frontiers in Immunology, 2022, 13: 907808.

Protocole (Protocol)

Cell experiment [1]:

Cell lines

 Colon 205 cells

Preparation Method

 Colon 205 cells were cultured in RPMI 1640 medium, supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, at 37°C in an incubator with 5% CO2. Culture wells containing 106 cells/well were incubated with LPS alone (1μg/ml) or LPS + (S)-(-)-Levamisole (0, 1, 10, 100, and 1000µM) at 37°C in 5% CO2 for 24h. The supernatant was frozen at -80°C until the measurement of PGE2 by ELISA.

Reaction Conditions

 0, 1, 10, 100, and 1000µM; 24h

Applications

 (S)-(-)-Levamisole treatment markedly decreased LPS-induced PGE2 production in Colon 205 cells in a dose-dependent manner.
Animal experiment [2]:

Animal models

 Female BALB/cA nu/nu mice

Preparation Method

Female BALB/cA nu/nu mice (6 weeks old) were housed under controlled conditions with a relative humidity of 55%±5%, room temperature maintained at 23°C-24°C, and a 12h light/dark cycle. HABC-1 were transplanted subcutaneously on both flanks of mice, treatment was not initiated until 2 weeks after transplantation. Mice were either left untreated or treated three times a week for four consecutive weeks with subcutaneous injections of 12mg/kg (S)-(-)-Levamisole, or PBS. Tumor sizes were measured three times a week for 4 weeks.

Dosage form

12mg/kg; three times a week; 4 weeks; s.c.

Applications

(S)-(-)-Levamisole treatment inhibited tumor growth in mice with HABC-1 xenografts.
References:
[1] Liu M S C Y, Lai M S Y Y, Lo M D C J. Levamisole modulates prostaglandin E2 production and cyclooxygenase II gene expression in human colonic cancer cells[J]. Journal of Surgical Research, 2004, 117(2): 223-231.
[2] Friis T, Engel A M, Klein B M, et al. Levamisole inhibits angiogenesis in vitro and tumor growth in vivo[J]. Angiogenesis, 2005, 8(1): 25-34.

Documents produit (Product Documents)

Purity:>97.00%Appearance:A solid
COASDSData Sheet

Propriétés chimiques (Chemical Properties)

N° CAS
14769-73-4
Formule moléculaire
C11H12N2S
Masse moléculaire
204.29
Solubilité
DMSO : 100 mg/mL (489.50 mM; Need ultrasonic)
Conservation
Store at -20°C
Conseils généraux
Choisissez un solvant adapté selon les données de solubilité du produit. Après préparation, répartissez la solution mère en aliquotes afin d’éviter les cycles répétés de congélation-décongélation.
Utilisez les solutions mères dans les 6 mois si elles sont conservées à -80°C, ou dans le mois si elles sont conservées à -20°C.
Pour améliorer la solubilité, réchauffez le tube à 37°C et soniquez-le pendant une durée appropriée.
Conditions d’expédition
Les échantillons d’évaluation sont expédiés avec des blocs réfrigérants. Les autres formats sont expédiés à température ambiante ou, sur demande, avec des blocs réfrigérants.

Calculateurs (Calculators)Molarité / Dilution / Masse moléculaire / Conversion d’unités / Formulation in vivo / Solubilité

g/mol

Reviews

Review for (S)-(-)-Levamisole

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%